Rezolute, Inc. (RZLT) Stock Price & Analysis
Rezolute, Inc. (RZLT) fell 6.03% to USD 4.99 as of July 25, 2026 at 07:11 UTC, according to Nexqual real-time market data.
RZLT last closed at USD 5.31; the session ranged USD 4.9–5.31 on volume of 1,146,629 shares. Market capitalization is $480.50M, with a 52-week range of USD 1.07–11.46 (NCM). Source: Nexqual, July 25, 2026 at 07:11 UTC.
Key Statistics (as of July 25, 2026 at 07:11 UTC)
| Price | USD 4.99 |
|---|---|
| Change | ▼ 6.03% (down) |
| Previous Close | USD 5.31 |
| Open | USD 5.31 |
| Day Range | USD 4.9 – 5.31 |
| 52-Week Range | USD 1.07 – 11.46 |
| Volume | 1,146,629 shares |
| Market Cap | $480.50M |
| Exchange | NCM |
Technical Analysis (RZLT)
Nexqual's technical model rates RZLT "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 07:11 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.74 (neutral) |
| vs SMA50 | Above (USD 4.34) |
| MACD | 0.15 (positive) |
Analyst Ratings (RZLT)
Wall Street analysts rate RZLT "None" based on 9 analysts, with a mean price target of USD 7.67 (range USD 4–14), per Nexqual as of July 25, 2026 at 07:11 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 7.67 |
| High Target | USD 14 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 8 / 2 / 0 |
Earnings (RZLT)
| Next Earnings Date | 2026-09-16 |
|---|---|
| EPS Estimate | USD -0.14 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.22 vs est -0.18 ▼ miss |
| 2025-09-30 | USD -0.18 vs est -0.26 ▲ beat |
| 2025-06-30 | USD -0.26 vs est -0.24 ▼ miss |
Source: Nexqual, July 25, 2026 at 07:11 UTC.
Financials & Fundamentals (RZLT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -81.73% |
| Debt / Equity | 0.95 |
| Current Ratio | 15.84 |
| Total Cash | $120.27M |
| Total Debt | $1.11M |
| Free Cash Flow | $-43.71M |
Source: Nexqual, July 25, 2026 at 07:11 UTC.
Financial Health Score (RZLT)
Nexqual rates Rezolute, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 07:11 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $120M cash vs $1M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$73M |
| Efficiency | Critical — ROE -82%, ROA -48.7% |
Ownership (RZLT)
| Insider Ownership | +10.15% |
|---|---|
| Institutional Ownership | +90.63% |
| Shares Outstanding | 96.29M |
| Float | 66.01M |
| Short % of Float | +25.50% |
Source: Nexqual, July 25, 2026 at 07:11 UTC.
Leadership (RZLT)
Rezolute, Inc. is led by Nevan Charles Elam (age 58), Founder, CEO, Principal Financial Officer & Acting Chairman of the Board, per Nexqual as of July 25, 2026 at 07:11 UTC.
| Founder, CEO, Principal Financial Officer & Acting Chairman of the Board | Nevan Charles Elam (age 58) |
|---|---|
| Chief Financial & Business Officer | Daron G. Evans M.B.A., M.S. (age 51) |
| Director and Head of Scientific & Patient Affairs | Davelyn Eaves Hood |
| Senior Director of People and Culture | Melissa Quinn |
Major Backers & Investors (RZLT)
Notable institutional backers of Rezolute, Inc. include Jennison Associates LLC, Siren, L.L.C., Bank of America Corporation, according to Nexqual as of July 25, 2026 at 07:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Jennison Associates LLC | 40.85% |
| Siren, L.L.C. | 39.54% |
| Bank of America Corporation | 35.29% |
| Fidelity | 13.9% |
| Charles Schwab | 4.97% |
Source: Nexqual, July 25, 2026 at 07:11 UTC.
From Rezolute, Inc.'s Latest SEC 10-K Filing (filed 2025-09-17)
Key Strengths & Strategy (as disclosed to the SEC)
- Research and Development We incurred approximately $61.5 million and $55.7 million in research and development expenses for the fiscal years ended June 30, 2025 and 2024, respectively.
- We believe that a rich culture of inclusion and diversity enables us to create, develop and fully leverage the strengths of our workforce.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LRMR | Larimar Therapeutics, Inc. | USD 4 | ▼ 0.5% |
| ELDN | Eledon Pharmaceuticals, Inc. | USD 3.58 | ▼ 3.76% |
| TRVI | Trevi Therapeutics, Inc. | USD 17.54 | ▲ 1.01% |
| TARA | Protara Therapeutics, Inc. | USD 4.02 | ▼ 1.47% |
| JSPR | Jasper Therapeutics, Inc. | USD 0.69 | ▼ 7.6% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:11 UTC. This page is informational and not investment advice.